Fundraising Fox
Ymabs
Founded 2015 · 54 employees on LinkedIn · 1 known investors
Find your way into Ymabs
Sign up to see every warm intro you have to Ymabs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ymabs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.
Founders & leadership
Ymabs was founded in 2015 by Thomas Gad.
Investors · 1
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 2
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Ymabs.
Frequently asked questions
- What does Ymabs do?
- Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.
- Who founded Ymabs?
- Ymabs was founded by Thomas Gad in 2015.
- Who are Ymabs's investors?
- Ymabs's investors include Sofinnova Ventures.